biguanides has been researched along with Fasting Hypoglycemia in 68 studies
Biguanides: Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES.
biguanides : A class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.
Fasting Hypoglycemia: HYPOGLYCEMIA expressed in the postabsorptive state, after prolonged FASTING, or an overnight fast.
Excerpt | Relevance | Reference |
---|---|---|
"The therapeutic effect of short-term buformin (l-butylbiguanide) treatment was investigated in 12 patients with reactive hypoglycemia." | 7.65 | Treatment of reactive hypoglycemia with buformin. ( Cabrijan, T; Sekso, M; Solter, M; Zjacić, V, 1975) |
" Weight loss was greater in patients with lower baseline HbA1c and in patients taking concomitant biguanides." | 5.22 | Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes. ( Iwamoto, N; Nishiyama, H; Ohyama, S; Onishi, Y; Oura, T; Takeuchi, M, 2016) |
" As an essential complication provoked by biguanides a lactic acidosis may be elicited which--though seldom occurring--then in most cases takes a fatal course." | 3.67 | [Drug-induced harm due to antidiabetics]. ( Verlohren, HJ, 1984) |
" The most dangerous side-effect of biguanides is lactic acidosis." | 3.67 | Incidence of severe sideeffects during therapy with sulfonylureas and biguanides. ( Berger, W, 1985) |
"The therapeutic effect of short-term buformin (l-butylbiguanide) treatment was investigated in 12 patients with reactive hypoglycemia." | 3.65 | Treatment of reactive hypoglycemia with buformin. ( Cabrijan, T; Sekso, M; Solter, M; Zjacić, V, 1975) |
" The overall incidence of treatment-emergent adverse events (TEAEs) was 75." | 2.82 | Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study. ( Enya, K; Kaku, K; Matsuno, R; Nakaya, R; Ohira, T, 2016) |
" The most frequent adverse events with dulaglutide treatment were nasopharyngitis and gastrointestinal symptoms." | 2.80 | Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study. ( Araki, E; Imaoka, T; Inagaki, N; Oura, T; Takeuchi, M; Tanizawa, Y, 2015) |
"In the treatment of elderly type 2 diabetes, it is important to detect hypoglycemia correctly, because the elderly patients often exhibit atypical symptoms from hypoglycemia." | 2.43 | [Knack of treatment with oral hypoglycemic drugs in the elderly]. ( Hashizume, K; Komatsu, M, 2006) |
"Currently available oral agents for the treatment of type 2 diabetes mellitus include a variety of compounds from 5 different pharmacologic classes with differing mechanisms of action, adverse effect profiles, and toxicities." | 2.41 | Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment. ( Beattie, P; Harrigan, RA; Nathan, MS, 2001) |
"Nocturnal hypoglycemia is a serious complication of insulin-treated diabetes, and it is often asymptomatic." | 1.56 | A Novel CGM Metric-Gradient and Combining Mean Sensor Glucose Enable to Improve the Prediction of Nocturnal Hypoglycemic Events in Patients with Diabetes. ( Bao, Y; Kandwal, A; Li, J; Liu, Y; Lu, J; Lu, W; Ma, X; Nie, Z; Tobore, I; Wang, L; Zhou, J, 2020) |
" At the same time about 1/3 of these serious adverse drug reactions (ADR) was found to have been reported to the ADR-register." | 1.27 | Drug utilization and morbidity statistics for the evaluation of drug safety in Sweden. ( Westerholm, B; Wiholm, BE, 1984) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 54 (79.41) | 18.7374 |
1990's | 3 (4.41) | 18.2507 |
2000's | 3 (4.41) | 29.6817 |
2010's | 7 (10.29) | 24.3611 |
2020's | 1 (1.47) | 2.80 |
Authors | Studies |
---|---|
Li, J | 1 |
Ma, X | 1 |
Tobore, I | 1 |
Liu, Y | 1 |
Kandwal, A | 1 |
Wang, L | 1 |
Lu, J | 1 |
Lu, W | 1 |
Bao, Y | 1 |
Zhou, J | 1 |
Nie, Z | 1 |
Kopecky, C | 1 |
Umetsu, R | 1 |
Nishibata, Y | 1 |
Abe, J | 1 |
Suzuki, Y | 1 |
Hara, H | 1 |
Nagasawa, H | 1 |
Kinosada, Y | 1 |
Nakamura, M | 1 |
Araki, E | 2 |
Tanizawa, Y | 2 |
Tanaka, Y | 1 |
Taniguchi, A | 1 |
Koiwai, K | 1 |
Kim, G | 1 |
Salsali, A | 1 |
Woerle, HJ | 1 |
Broedl, UC | 1 |
Inagaki, N | 1 |
Oura, T | 2 |
Takeuchi, M | 2 |
Imaoka, T | 1 |
Onishi, Y | 1 |
Nishiyama, H | 1 |
Ohyama, S | 1 |
Iwamoto, N | 1 |
Kaku, K | 1 |
Enya, K | 1 |
Nakaya, R | 1 |
Ohira, T | 1 |
Matsuno, R | 1 |
Grunberger, G | 1 |
Chen, L | 1 |
Rodriguez, A | 1 |
Tinahones, FJ | 1 |
Jacober, SJ | 1 |
Bue-Valleskey, J | 1 |
Ben Amara, H | 1 |
Kacem, A | 1 |
Gaigi, I | 1 |
Dakhli, S | 1 |
Ben Mami, F | 1 |
Achour, A | 1 |
STEINER, DF | 1 |
WILLIAMS, RH | 1 |
FALCONE, AB | 1 |
MAO, RL | 1 |
SHRAGO, E | 1 |
KANEKO, T | 1 |
Komatsu, M | 1 |
Hashizume, K | 1 |
Verlohren, HJ | 1 |
Auzepy, P | 1 |
Caquet, R | 1 |
Lefèbvre, PJ | 1 |
Luyckx, AS | 1 |
Gérard, J | 1 |
Wiholm, BE | 1 |
Westerholm, B | 1 |
Luk'ianchikov, VS | 1 |
Czyzyk, A | 1 |
Stryjek-Kamińska, D | 1 |
Krentz, AJ | 1 |
Ferner, RE | 1 |
Bailey, CJ | 1 |
Tasaka, Y | 1 |
Ishii, J | 1 |
Inoue, I | 1 |
Harrigan, RA | 1 |
Nathan, MS | 1 |
Beattie, P | 1 |
Gay, G | 1 |
Debry, G | 1 |
Haslbeck, M | 1 |
Permutt, MA | 1 |
Sauer, H | 1 |
Schneider, B | 1 |
Schäfer, G | 1 |
Constam, GR | 1 |
Sekso, M | 1 |
Solter, M | 1 |
Zjacić, V | 1 |
Cabrijan, T | 1 |
Rett, K | 1 |
Wicklmayr, M | 1 |
Dietze, GJ | 1 |
Berger, W | 3 |
Solé Violán, J | 1 |
Martínez Chuecos, J | 1 |
Molinero Somolinos, F | 1 |
Marco Moreno, JM | 1 |
Wolff, G | 2 |
Stowers, JM | 1 |
Scoville, AB | 1 |
Losert, W | 4 |
Loge, O | 4 |
Schillinger, E | 4 |
Kraaz, W | 3 |
Haeckel, R | 1 |
De Luca, E | 1 |
Pellegrini, M | 1 |
Ito, T | 1 |
Davidoff, F | 1 |
Hermann, LS | 1 |
Bäbler, M | 1 |
Jahn, P | 2 |
Mashimo, K | 1 |
Nakagawa, S | 1 |
Hanai, N | 1 |
Tschudi-Steiner, I | 1 |
Mehnert, H | 1 |
Breidahl, HD | 1 |
Martin, FI | 1 |
Semple, B | 1 |
Walpole, GR | 1 |
Shepherd, DU | 1 |
Proust, AJ | 1 |
Harcourt, D | 1 |
Consiglio, D | 1 |
Mantia, G | 1 |
Hopps, V | 1 |
Ziegelasch, HJ | 1 |
Koller, F | 1 |
Pirart, J | 1 |
Elpern, B | 1 |
Lotz, U | 1 |
Accettella, U | 1 |
Sacra, A | 1 |
Gentile, M | 1 |
Stötter, G | 1 |
Raptis, S | 1 |
Rothenbuchner, G | 1 |
Pfeiffer, EF | 1 |
Rosenbloom, AL | 1 |
Jangaard, NO | 1 |
Pereira, JN | 1 |
Pinson, R | 1 |
Böhm, E | 1 |
Gutsche, H | 1 |
Höpker, W | 1 |
Boenicke, G | 1 |
Müting, D | 1 |
Yoh, YJ | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A 52-week, Randomised, Multi-centre, Parallel Group Study to Investigate the Safety and Efficacy of BI 10773 (10 mg or 25 mg Administered Orally Once Daily) as add-on Therapy to an Oral Antidiabetic Drug (Sulfonylurea, Biguanide, Thiazolidinedione, Alpha [NCT01368081] | Phase 3 | 1,162 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Change from baseline in HbA1c after 52 weeks of treatment (NCT01368081)
Timeframe: Baseline and 52 weeks
Intervention | percentage of HbA1c (Least Squares Mean) |
---|---|
Sulfonylurea: Empa 10mg | -0.93 |
Sulfonylurea: Empa 25mg | -0.96 |
Sulfonylurea: Metformin | -0.97 |
Biguanide: Empa 10mg | -0.81 |
Biguanide: Empa 25mg | -0.98 |
Thiazolidinedione: Empa 10mg | -0.90 |
Thiazolidinedione: Empa 25mg | -0.96 |
Alpha Glucosidase Inhibitor: Empa 10mg | -0.87 |
Alpha Glucosidase Inhibitor: Empa 25mg | -0.77 |
DPP-IV Inhibitor: Empa 10mg | -1.00 |
DPP-IV Inhibitor: Empa 25mg | -0.83 |
Glinide: Empa 10mg | -0.98 |
Glinide: Empa 25mg | -0.98 |
Number of patients with confirmed hypoglycaemic adverse events (NCT01368081)
Timeframe: After the first drug intake until 7 days after the last treatment administration, up to 383 days
Intervention | participants (Number) |
---|---|
Sulfonylurea: Empa 10mg | 6 |
Sulfonylurea: Empa 25mg | 9 |
Sulfonylurea: Metformin | 5 |
Biguanide: Empa 10mg | 0 |
Biguanide: Empa 25mg | 1 |
Thiazolidinedione: Empa 10mg | 2 |
Thiazolidinedione: Empa 25mg | 1 |
Alpha Glucosidase Inhibitor: Empa 10mg | 0 |
Alpha Glucosidase Inhibitor: Empa 25mg | 0 |
DPP-IV Inhibitor: Empa 10mg | 0 |
DPP-IV Inhibitor: Empa 25mg | 1 |
Glinide: Empa 10mg | 0 |
Glinide: Empa 25mg | 2 |
Number of Patients With Drug Related Adverse Events after the first drug intake until 7 days after the last treatment administration, up to 383 days (NCT01368081)
Timeframe: After the first drug intake until 7 days after the last treatment administration, up to 383 days
Intervention | participants (Number) |
---|---|
Sulfonylurea: Empa 10mg | 19 |
Sulfonylurea: Empa 25mg | 25 |
Sulfonylurea: Metformin | 13 |
Biguanide: Empa 10mg | 13 |
Biguanide: Empa 25mg | 9 |
Thiazolidinedione: Empa 10mg | 20 |
Thiazolidinedione: Empa 25mg | 19 |
Alpha Glucosidase Inhibitor: Empa 10mg | 7 |
Alpha Glucosidase Inhibitor: Empa 25mg | 5 |
DPP-IV Inhibitor: Empa 10mg | 9 |
DPP-IV Inhibitor: Empa 25mg | 18 |
Glinide: Empa 10mg | 9 |
Glinide: Empa 25mg | 9 |
23 reviews available for biguanides and Fasting Hypoglycemia
Article | Year |
---|---|
Use of noninsulin antidiabetic medications in hospitalized patients.
Topics: Benzamides; Biguanides; Bromocriptine; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Glycos | 2013 |
[Diabetes mellitus of elderly patients: therapeutic recommendations].
Topics: Aged; Aging; Biguanides; Blood Glucose; Cachexia; Diabetes Mellitus, Type 2; Diabetic Neuropathies; | 2008 |
[Knack of treatment with oral hypoglycemic drugs in the elderly].
Topics: Aged; Biguanides; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glyburide; Humans; Hypoglyce | 2006 |
[Severe hypoglycemia due to insulin. Risks and adverse effects of antidiabetic drugs].
Topics: Acidosis; Aged; Biguanides; Brain Diseases; Digestive System Diseases; Drug Eruptions; Drug Interact | 1983 |
[Syndrome of reactive hypoglycemia. Myth or reality].
Topics: Acarbose; Alcoholic Intoxication; Biguanides; Blood Glucose; Calcium; Dietary Fiber; Drug Synergism; | 1983 |
[Adverse effects and interactions of oral antidiabetics].
Topics: Administration, Oral; Biguanides; Diabetes Mellitus; Drug Interactions; Ethanol; Gastrointestinal Di | 1980 |
Comparative tolerability profiles of oral antidiabetic agents.
Topics: Acarbose; Administration, Oral; Biguanides; Biological Availability; Diabetes Mellitus, Type 2; Drug | 1994 |
[Indication and method of administration of oral antidiabetic agents].
Topics: Administration, Oral; Biguanides; Diabetes Mellitus; Diet, Diabetic; Drug Interactions; Exercise The | 1997 |
[Measures to meet the side effects of the orally administered antihyperglycemic drugs].
Topics: Acarbose; Administration, Oral; Animals; Biguanides; Cardiovascular System; Chromans; Drug Interacti | 1997 |
Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment.
Topics: Administration, Oral; Benzoates; Biguanides; Blood Glucose; Diabetes Mellitus, Type 2; Drug Interact | 2001 |
[New aspects of therapy with oral antidiabetic agents].
Topics: Acidosis; Biguanides; Blood Proteins; Chlorpropamide; Diabetes Mellitus; Diabetic Nephropathies; Dru | 1979 |
Postprandiol hypoglycemia.
Topics: Administration, Oral; Adult; Biguanides; Blood Glucose; Diabetes Mellitus; Diet Therapy; Eating; Eva | 1976 |
[What is achieved by the therapy with oral antidiabetics?].
Topics: Administration, Oral; Adult; Biguanides; Chlorpropamide; Diabetes Mellitus; Diabetic Angiopathies; D | 1976 |
[Hypoglycemia. 3].
Topics: Animals; Arginine; Biguanides; Diazoxide; Dicumarol; Drug Synergism; Ethanol; Glucagon; Glucocortico | 1970 |
Oral treatment in diabetes.
Topics: Acetohexamide; Acidosis; Administration, Oral; Animals; Biguanides; Cardiovascular Diseases; Chlorpr | 1972 |
[Inhibitors of hepatic gluconeogenesis and their significance in medicine].
Topics: Animals; Biguanides; Chemical Phenomena; Chemistry; Chickens; Columbidae; Cricetinae; Cytoplasm; Dog | 1972 |
[Oral antidiabetics].
Topics: Acidosis; Biguanides; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Gastrointesti | 1972 |
Guanidine derivatives in medicine.
Topics: Animals; Axons; Biguanides; Binding Sites; Binding, Competitive; Calcium; Cations, Divalent; Cations | 1973 |
Biguanides and lactate metabolism: a review.
Topics: Acidosis; Animals; Biguanides; Blood Glucose; Carbon Radioisotopes; Diabetes Mellitus; Gluconeogenes | 1973 |
[Hypoglycemia. 3].
Topics: Biguanides; Cyclophosphamide; Diet, Diabetic; Ethanol; Glucagon; Humans; Hypoglycemia; Hypoglycemic | 1968 |
[Evaluation of therapy of diabetes mellitus with oral antidiabetics].
Topics: Adult; Biguanides; Chemical Phenomena; Chemistry; Diabetes Mellitus; Diet, Diabetic; Female; Humans; | 1969 |
[Adverse effects of important long-term-therapeutics].
Topics: Acidosis; Animals; Antidepressive Agents; Antitubercular Agents; Biguanides; Central Nervous System; | 1970 |
Glibenclamide: a review.
Topics: Administration, Oral; Adolescent; Adult; Aged; Animals; Biguanides; Blood Glucose; Carbon Isotopes; | 1971 |
7 trials available for biguanides and Fasting Hypoglycemia
Article | Year |
---|---|
Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Benzhydryl Compounds; Biguanides; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl- | 2015 |
Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study.
Topics: Aged; Biguanides; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Administration Schedul | 2015 |
Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes.
Topics: Aged; Biguanides; Body Mass Index; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Blin | 2016 |
Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study.
Topics: Benzofurans; Biguanides; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitor | 2016 |
A randomized clinical trial of basal insulin peglispro vs NPH in insulin-naïve patients with type 2 diabetes: the IMAGINE 6 trial.
Topics: Aged; Alanine Transaminase; Biguanides; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptida | 2016 |
Comparative tolerability profiles of oral antidiabetic agents.
Topics: Acarbose; Administration, Oral; Biguanides; Biological Availability; Diabetes Mellitus, Type 2; Drug | 1994 |
[On the effect of a new depot biguanide on carbohydrate and protein metabolism in diabetes mellitus].
Topics: Biguanides; Carbohydrate Metabolism; Diabetes Mellitus; Female; Humans; Hypoglycemia; Insulin; Male; | 1966 |
39 other studies available for biguanides and Fasting Hypoglycemia
Article | Year |
---|---|
A Novel CGM Metric-Gradient and Combining Mean Sensor Glucose Enable to Improve the Prediction of Nocturnal Hypoglycemic Events in Patients with Diabetes.
Topics: Aged; Biguanides; Blood Glucose; Blood Glucose Self-Monitoring; Circadian Rhythm; Diabetes Mellitus, | 2020 |
[Evaluation of the association between the use of oral anti-hyperglycemic agents and hypoglycemia in Japan by data mining of the Japanese Adverse Drug Event Report (JADER) database].
Topics: Acarbose; Administration, Oral; Adverse Drug Reaction Reporting Systems; Benzamides; Biguanides; Dat | 2014 |
Respiratory inhibition and hypoglycemia by biguanides and decamethylenediguanidine.
Topics: Antineoplastic Agents; Biguanides; Humans; Hypoglycemia; Hypoglycemic Agents; Metabolism | 1958 |
A study of the action of hypoglycemia-producing biguanide and sulfonylurea compounds on oxidative phosphorylation.
Topics: Biguanides; Humans; Hypoglycemia; Hypoglycemic Agents; Liver; Mitochondria; Oxidative Phosphorylatio | 1962 |
[STUDIES ON THE MODE OF ACTION OF HYPOGLYCEMIC BIGUANIDES].
Topics: Adenosine Triphosphate; Alanine Transaminase; Aspartate Aminotransferases; Biguanides; Carbohydrate | 1963 |
[Drug-induced harm due to antidiabetics].
Topics: Abnormalities, Drug-Induced; Acidosis; Biguanides; Bone Marrow; Cardiovascular Diseases; Chemical an | 1984 |
Drug utilization and morbidity statistics for the evaluation of drug safety in Sweden.
Topics: Acidosis; Aged; Anti-Infective Agents, Urinary; Biguanides; Congenital Abnormalities; Contraceptives | 1984 |
[Diagnosis and treatment of hypoglycemia syndrome].
Topics: Biguanides; Blood Glucose; Diagnosis, Differential; Diet; Glucose Tolerance Test; Humans; Hypoglycem | 1982 |
[Drug-induced hypoglycemia in diabetic patients].
Topics: Adrenergic beta-Antagonists; Biguanides; Diabetes Mellitus; Hypoglycemia; Hypoglycemic Agents; Insul | 1976 |
Some new aspects on the interaction of hypoglycemia-producing biguanides with biological membranes.
Topics: Animals; Biguanides; Columbidae; Energy Metabolism; Gluconeogenesis; Guinea Pigs; Hypoglycemia; In V | 1976 |
[Therapeutical principles and drug therapy of diabetes in adults].
Topics: Adult; Biguanides; Chemical Phenomena; Chemistry; Diabetes Mellitus; Diabetic Coma; Diet, Diabetic; | 1975 |
Treatment of reactive hypoglycemia with buformin.
Topics: Adult; Biguanides; Blood Glucose; Buformin; Female; Glucose Tolerance Test; Humans; Hypoglycemia; In | 1975 |
Hypoglycemia in hypertensive diabetic patients treated with sulfonylureas, biguanides, and captopril.
Topics: Biguanides; Captopril; Diabetes Mellitus, Type 2; Drug Synergism; Drug Therapy, Combination; Female; | 1988 |
[Incidence of severe secondary effects during treatment with sulfonylureas and biguanides].
Topics: Adult; Aged; Biguanides; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemia; Inappropriate ADH | 1986 |
Incidence of severe sideeffects during therapy with sulfonylureas and biguanides.
Topics: Acidosis; Biguanides; Chlorpropamide; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemia; Hypog | 1985 |
[Overdose of biguanides].
Topics: Acidosis; Adolescent; Biguanides; Buformin; Female; Humans; Hypoglycemia; Lactates; Lactic Acid | 1985 |
Editorial: Oral therapy in diabetes mellitus.
Topics: Acetohexamide; Biguanides; Chlorpropamide; Diabetes Mellitus; Diabetic Ketoacidosis; Diet Therapy; H | 1974 |
[Hypoglycemia induced by N1-(n-butyl)-biguanide (Buformin) in animal experiments].
Topics: Animals; Arabinose; Biguanides; Blood Glucose; Diabetes Mellitus, Experimental; Hypoglycemia; Hypogl | 1969 |
[Enhancement of the hypoglycemic action of insulin by buformin in rats].
Topics: Animals; Biguanides; Carbon Dioxide; Carbon Isotopes; Drug Synergism; Glycogen; Hypoglycemia; Hypogl | 1970 |
[Complications in the therapy of diabetes using oral hypoglycemic agents].
Topics: Biguanides; Diabetes Mellitus; Diabetic Coma; Diet, Diabetic; Female; Humans; Hypoglycemia; Hypoglyc | 1974 |
[Oral antidiabetics].
Topics: Administration, Oral; Biguanides; Diabetes Mellitus; Gastrointestinal Diseases; Humans; Hypoglycemia | 1972 |
[Studies on the mode of action of biguanides in animals. 4. Studies on gamma-guanidinobutyramide and summary].
Topics: Amides; Animals; Biguanides; Blood Glucose; Butyrates; Carbon Isotopes; Diabetes Mellitus, Experimen | 1972 |
[Animal experimental studies on the mode of action of biguanides. 1. Studies with hypoglycemia-inducing doses of biguanide].
Topics: Animals; Biguanides; Blood Glucose; Carbon Isotopes; Diaphragm; Dose-Response Relationship, Drug; Fa | 1972 |
[Differential therapy using oral antidiabetics].
Topics: Administration, Oral; Biguanides; Blood Glucose; Chemical Phenomena; Chemistry; Diabetes Mellitus; D | 1971 |
Diabetes mellitus: diagnosis and treatment.
Topics: Acetone; Biguanides; Diabetes Complications; Diabetes Mellitus; Diabetic Ketoacidosis; Diet Therapy; | 1968 |
[Synergism between oral diabetics and insulin].
Topics: Animals; Biguanides; Blood Glucose; Chlorpropamide; Columbidae; Drug Synergism; Glyburide; Hypoglyce | 1971 |
[Extreme hypoglycemia during combined tolbutamide, n-1-butylbiguanide hydrochloride and chloramphenicol therapy].
Topics: Age Factors; Aged; Biguanides; Chloramphenicol; Diabetes Mellitus; Diabetic Angiopathies; Diabetic N | 1972 |
[The risk of hypoglycemia in sulfonylurea therapy].
Topics: Age Factors; Aged; Biguanides; Cerebrovascular Disorders; Diabetes Mellitus; Diet Therapy; Glucose T | 1972 |
Failure of the biguanides to improve the control of unstable diabetes treated with insulin.
Topics: Adolescent; Adult; Aged; Biguanides; Diabetes Mellitus; Drug Synergism; Female; Glycosuria; Humans; | 1971 |
Chemistry of the biguanides.
Topics: Alkylation; Benzene Derivatives; Biguanides; Chemical Phenomena; Chemistry; Chromium; Cobalt; Copper | 1968 |
[Extreme blood sugar depression from combined carbutamide-buformin therapy].
Topics: Aged; Biguanides; Carbutamide; Female; Humans; Hypoglycemia | 1969 |
[Hypoglycemic attacks caused by oral hypoglycemic drugs].
Topics: Aged; Biguanides; Chlorpropamide; Diabetes Mellitus; Diabetic Coma; Female; Humans; Hypoglycemia; Hy | 1970 |
[Hypoglycemia after treatment with Glibenclamid (Euglucon 5)].
Topics: Aged; Biguanides; Cyclohexanes; Diabetes Mellitus; Humans; Hypoglycemia; Hypoglycemic Agents; Male; | 1970 |
[Progress in the therapy of diabetes].
Topics: Adrenal Cortex Hormones; Adult; Aged; Aminocaproates; Animals; Biguanides; Blood Glucose; Child; Dia | 1971 |
The natural history of diabetes mellitus.
Topics: Biguanides; Child; Child, Preschool; Diabetes Mellitus; Glucose Tolerance Test; Humans; Hypoglycemia | 1971 |
Metabolic effects of the biguanides and possible mechanism of action.
Topics: Adipose Tissue; Animals; Biguanides; Biological Transport; Columbidae; Gluconeogenesis; Glucose; Gui | 1968 |
[On the forensic evaluation of hypoglycemia during treatment with oral anti-diabetics].
Topics: Accidents, Traffic; Aged; Biguanides; Blood Glucose; Diabetes Mellitus; Drug Synergism; Humans; Hypo | 1968 |
[Causes and prevention of hypoglycemia due to glibenclamide].
Topics: Aged; Biguanides; Diabetes Mellitus; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle | 1969 |
Pharmacological studies on n-butylbiguanide with special reference to hypoglycemic effect.
Topics: Animals; Autonomic Nervous System; Biguanides; Blood Glucose; Hypoglycemia; Male; Rabbits; Rats | 1966 |